The J. M. Smucker Company
—- Market cap
- $12.94B
- Debt
- +$6.96B
- Cash
- —
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 65% equity / 35% debt
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: SJM stock price vs AVTX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AVTX's multiple
Needs AVTX P/S.
Implied fair value · at SJM's multiple
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
12 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 65% equity / 35% debt
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
The J. M. Smucker Company · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
AVALO THERAPEUTICS, INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
COCA COLA CO
SJM vs KO
PEPSICO INC
SJM vs PEP
GENERAL MILLS INC
SJM vs GIS
COLGATE PALMOLIVE CO
SJM vs CL
Lamb Weston Holdings, Inc.
SJM vs LW
HORMEL FOODS CORP /DE/
SJM vs HRL
CytomX Therapeutics, Inc.
SJM vs CTMX
IDEAYA Biosciences, Inc.
SJM vs IDYA
Ocugen, Inc.
SJM vs OCGN
CLOVER HEALTH INVESTMENTS, CORP. /DE
SJM vs CLOV
Citius Pharmaceuticals, Inc.
SJM vs CTXR
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe SJM’s margins can remain stable and that AVTX is not an appropriate AVTX for valuation, then avoid relying on AVTX-implied price and instead anchor to SJM’s historical and DCF ranges because the current comp-based upside is mechanically distorted by AVTX’s tiny revenue base.
The implied price of $1,424,333.81 versus SJM’s current price of $116.28 indicates an extreme valuation gap driven almost entirely by AVTX’s tiny revenue base and astronomical P/S ratio. This is not a clean AVTX comparison, but it does show that using AVTX as the comp produces an economically meaningless multiple for SJM.
Supporting Metrics